Načítá se...
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Although around 80% of endometrial cancers are diagnosed at early stages and present with a 5-year survival rate exceeding 95%, patients with advanced and recurrent disease show a poor prognosis and low response rates to standard chemotherapy. In the era of targeted therapy, the great advances in th...
Uloženo v:
| Vydáno v: | J Clin Med |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7356971/ https://ncbi.nlm.nih.gov/pubmed/32503218 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9061721 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|